Here,a new LNP platform for simultaneous delivery of SMAD3 siRNAand COL1A1 mRNA was developed by using microfluidics technology asa potential therapeutic approach for treating tendinopathy. The gene discussed is COL1A1; the disease is disease of the tendon.